| Size | Price | Stock | Qty |
|---|---|---|---|
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
|
Cefuroxime Sodium (Zinacef) is a 2nd-generation cephalosporin antibiotic used to treat and prevent a number of bacterial infections including pneumonia, meningitis, otitis media, sepsis, urinary tract infections, and Lyme disease.
| ln Vitro |
Cefuroxime sodium exhibits great efficacy against Staphylococcus aureus (MIC=0.25 μg/ml), irrespective of the strain's penicillinase production. The minimum inhibitory concentration (MIC) values for methicillin-susceptible Staphylococcus aureus, methicillin-resistant Staphylococcus pyogenes, Streptococcus pneumoniae, viridans Streptococcus, Streptococcus faecalis, and Clostridium spp. are 0.25 μg/ml, 5.9 μg/ml, 0.125 μg/ml, 0.125 μg/ml, >125.0 μg/ml, and 1.2 μg/ml, respectively [1]. Even while cefuroxime sodium (10-100 μg/ml; 2–6) acts slowly on Staphylococcus aureus strains, it nonetheless has a fast bactericidal impact and can kill over 99% of the initial strains in just 6 hours of inoculation. Gram-negative bacteria are promptly eliminated; in most situations, more than 99% of large inocula are eliminated in less than two hours; strains that generate beta-lactamases are eliminated at a rate that is equivalent to that of strains lacking the enzyme [1].
|
|---|---|
| ln Vivo |
Rabbits (body weight 2.0-2.5 kg) were intravenously injected with Staphylococcus aureus strain 630 (penicillinase-producing strain), and the protection test findings showed that the median effective dose of cefuroxime sodium was 3 mg/kg [2].
|
| References | |
| Additional Infomation |
Cefuroxime sodium is an organic molecular entity.
Cefuroxime Sodium is the sodium salt form of cefuroxime and a semi-synthetic, broad-spectrum, beta-lactamase resistant, second-generation cephalosporin antibiotic with bactericidal activity. Cefuroxime sodium inhibits bacterial cell wall synthesis by inactivating penicillin binding proteins (PBPs) thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of the cell wall. Lack of cross-linking results in a reduction of cell wall stability and leads to cell lysis. Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS. See also: Cefuroxime (has active moiety). |
| Molecular Formula |
C16H15N4NAO8S
|
|---|---|
| Molecular Weight |
446.3671
|
| Exact Mass |
446.05
|
| CAS # |
56238-63-2
|
| Related CAS # |
Cefuroxime;55268-75-2;Cefuroxime axetil;64544-07-6;Cefuroxime-d3;1803240-98-3
|
| PubChem CID |
23670318
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
240-245°C(dec)
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
30
|
| Complexity |
804
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CO/N=C(/C1=CC=CO1)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)[O-].[Na+]
|
| InChi Key |
URDOHUPGIOGTKV-JTBFTWTJSA-M
|
| InChi Code |
InChI=1S/C16H16N4O8S.Na/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20;/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24);/q;+1/p-1/b19-9-;/t10-,14-;/m1./s1
|
| Chemical Name |
sodium;(6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~224.03 mM)
H2O : ~50 mg/mL (~112.01 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 55 mg/mL (123.22 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2403 mL | 11.2015 mL | 22.4029 mL | |
| 5 mM | 0.4481 mL | 2.2403 mL | 4.4806 mL | |
| 10 mM | 0.2240 mL | 1.1201 mL | 2.2403 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05609240 | Recruiting | Drug: Cefuroxime | Antibiotic Prophylaxis Colorectal Surgery |
University of Leeds | 2023-05-10 | Phase 2 | 2020-12-26
| NCT03141476 | Completed | Drug: Cefuroxime 1,5g Drug: Cefuroxime 3g Drug: Cefuroxime 4,5g |
Obesity; Drug | Universitätsklinikum Hamburg-Eppendorf | 2017-03-01 | Phase 4 |
| NCT06527560 | Recruiting | Drug: Cefuroxime Drug: Cefuroxime Axetil |
Pyelonephritis in Pregnancy | Hospital de Clinicas de Porto Alegre | 2024-09-09 | Phase 4 |
| NCT04616352 | Completed | Other: Resistance to cefuroxime | Urinary Tract Infections | Universidad Nacional de Colombia | 2020-12-26 | |
| Unknown status | NCT04212078 | Drug: Levofloxacin Ophthalmic Drug: Cefuroxime |
Endophthalmitis Postoperative | National University of Malaysia | 2019-07-29 | Phase 1 Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
